NCT07213817View on ClinicalTrials.gov

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

October 30, 2028

Study Completion Date

October 30, 2028

Conditions
Locally Advanced Solid TumorMetastatic Solid Tumor
Interventions
BIOLOGICAL

IPN60300

IPN60300 will be administered at assigned dose level.

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT07213817 - A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours | Biotech Hunter | Biotech Hunter